Start with the disorder, not the appetite headline
Binge-eating disorder is not simply enjoying food, feeling hungry or thinking frequently about the next meal. NIDDK describes a condition involving repeated loss-of-control eating and distress that deserves professional assessment. Appetite suppression therefore cannot stand in for a diagnosis or recovery measure. If you are seeking help, describe the experiences that concern you in your own words, including any restrictive eating or compensatory behavior. A short weight-loss questionnaire may not capture the problem you need treated. I would begin by asking who will evaluate the eating symptoms and how that care will be coordinated.[3]
The randomized pilot gives a more restrained answer
A 17-week placebo-controlled pilot enrolled 27 adults with binge-eating disorder and BMI of at least 27. Weekly objective binge episodes declined in both groups, and the difference between liraglutide and placebo was not statistically significant. Remission rates also did not differ significantly, although weight loss favored liraglutide. The investigators reported a medication-dispensing error as a limitation. These details are more informative than calling the trial a success or failure without naming the endpoint. The small sample leaves uncertainty, but a weight result does not repair an unproven effect on the primary binge-eating outcome.[1]
| Outcome at 17 weeks | Liraglutide | Placebo |
|---|---|---|
| Participants randomized | 13 | 14 |
| Binge-eating remission | 44% | 36% |
| Average weight loss | 5.2% | 0.9% |
Pilot randomized trial with 27 adults. Binge-remission and primary weekly binge-episode differences were not statistically significant. Weight loss favored liraglutide. A reported dispensing error limits interpretation; these are not personal outcome forecasts. Source: Allison and colleagues: randomized liraglutide pilot for binge-eating disorder.
Why the semaglutide chart review is encouraging but weaker
A retrospective semaglutide study reported larger improvements in Binge Eating Scale scores in the semaglutide-only group than in some other treatment groups. Participants were not randomly assigned, and a symptom-scale change is not the same as independently demonstrating long-term remission. Treatment selection, concurrent support and differences between patients can affect a chart review. I would treat the report as a reason for a better controlled study, rather than proof that semaglutide outperforms established eating-disorder care. The exact drug and design should remain attached to the claim; it is not a result for every GLP-1.[2]
Food noise is not a clinical substitute
People may use food noise to describe very different experiences, from persistent cravings to distressing preoccupation. That makes it a useful conversation starter but a poor shortcut for the trial endpoints above. Ask what change matters most to you: fewer loss-of-control episodes, less distress, more regular eating, improved functioning or something else. A scale can fall while an eating pattern remains difficult, and weight can change without resolving the disorder. Separating these goals prevents a before-and-after weight comparison from becoming the only evidence anyone considers at follow-up. We discuss the language and its limits in our food-noise evidence guide.
Treatment can involve more than a prescription
NICE recommends specific psychological approaches for binge-eating disorder and cautions against medication as the sole treatment. The guidance also distinguishes treatment of binge eating from weight-loss goals. That is a meaningful difference when an online program is built around a weight target. Ask whether the service can recognize and refer eating-disorder concerns, whether appropriate psychological support is available and whether your existing team can remain involved. A provider advertising coaching has not thereby established that it delivers specialist therapy. Clarify the professional role and actual service rather than assuming that similar words mean equivalent care.[4]
Make the intake honest even if it changes the options
Disclose a current or previous eating disorder, restrictive eating, purging, psychiatric treatment and the medicines you use through the clinician’s secure channel. These are relevant clinical details, not obstacles to work around to obtain a particular drug. A reputable evaluation may lead to a different care route than the one promoted on a landing page. I would also ask what symptoms should prompt contact between appointments and who reviews those messages. If the service cannot explain how it handles eating-disorder concerns, convenience and a low introductory price do not answer the care question. Use our appointment checklist to identify the care team and follow-up route before paying.
A useful follow-up conversation uses more than weight
Consider asking your treating team which symptoms and daily-life measures to follow. You might want to discuss loss of control, distress, restriction, social avoidance or difficulty maintaining regular meals, without self-assigning diagnostic thresholds. Agree on what information would be helpful and how it will be reviewed. This makes follow-up a conversation about health rather than a competition for the fastest weight change. It also gives you a way to explain an apparent contradiction, such as a lower scale reading alongside worsening food anxiety. The medication decision belongs within that broader clinical assessment. Before the visit, consider which ordinary activities the symptoms interfere with and what improvement would let you do differently. Those personal priorities can help the team choose meaningful follow-up questions without turning your records into a self-diagnosis.
Where a provider review can and cannot help
Our provider reviews can help you examine appointment access, billing and the service promised after enrollment. They cannot identify a binge-eating specialist or certify a treatment for this disorder. If obesity treatment is being considered alongside eating-disorder care, take the proposed service description back to your treating team before committing. I would want the clinical responsibilities named and the limits acknowledged. Evidence is still developing; neither the small randomized study nor the retrospective report supports replacing an established care relationship with an affiliate recommendation or a generic appetite-management package. Our LifeMD review covers its published weight-management service; confirm specialist needs separately before enrollment.
Put the questions to work
Compare our researched providers or build your provider checklist.
Continue your research
Sources & scope
Sources checked October 28, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
- Allison and colleagues: randomized liraglutide pilot for binge-eating disorder
- Richards and colleagues: retrospective semaglutide cohort
- NIDDK: binge-eating disorder overview and care
- NICE: eating-disorder treatment recommendations
Prices and terms can change. Confirm your specific offer directly with the provider.